Cargando…

Cost–Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels

To evaluate the cost–utility of pembrolizumab versus chemotherapy as the first-line setting for metastatic non-small cell lung cancer (NSCLC) from the US health care system perspective, a Markov model was developed to compare the lifetime cost and effectiveness of pembrolizumab versus chemotherapy f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weng, Xiuhua, Luo, Shaohong, Lin, Shen, Zhong, Lixian, Li, Meiyue, Xin, Rao, Huang, Pinfang, Xu, Xiongwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cognizant Communication Corporation 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851532/ https://www.ncbi.nlm.nih.gov/pubmed/31610828 http://dx.doi.org/10.3727/096504019X15707883083132

Ejemplares similares

The Predictive Value of PD-L1 Expression Level in Evaluating the Cost-Effectiveness of Atezolizumab/Pembrolizumab
por: Lin, Shen, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Hepatic Arterial Infusion of FOLFOX Combined Sorafenib for Advanced Hepatocellular Carcinoma With Portal Vein Invasion
por: Li, Meiyue, et al.
Publicado: (2021)

The correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworks
por: Lin, Shen, et al.
Publicado: (2023)

Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis
por: Huang, Xiaoting, et al.
Publicado: (2020)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
por: Liu, Qiao, et al.
Publicado: (2022)

Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC
por: Wan, Ning, et al.
Publicado: (2020)

Cost‐effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the first‐line treatment for advanced esophageal cancer
por: Ye, Zhuo‐Miao, et al.
Publicado: (2022)

Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States
por: Huang, Min, et al.
Publicado: (2017)

Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong
por: Loong, Herbert H., et al.
Publicado: (2019)

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
por: Reck, Martin, et al.
Publicado: (2021)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer
por: Wu, Meiyu, et al.
Publicado: (2022)

Disease burden of prostate cancer from 2014 to 2019 in the United States: estimation from the Global Burden of Disease Study 2019 and Medical Expenditure Panel Survey
por: Lin, Shen, et al.
Publicado: (2023)

Pembrolizumab alone or in combination with chemotherapy versus chemotherapy for advanced gastric cancer: A cost‐effectiveness analysis
por: Lang, Yitian, et al.
Publicado: (2023)

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
por: Zhou, Yixin, et al.
Publicado: (2019)

Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer
por: Chongqing, Tan, et al.
Publicado: (2021)

Pembrolizumab as first-line treatment for metastatic uveal melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
por: Kojima, Takashi, et al.
Publicado: (2022)

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
por: Takahashi, Shunji, et al.
Publicado: (2022)

Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy‐free, first‐line treatment for PD‐L1‐positive non‐small cell lung cancer
por: Zhou, Yixin, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More
por: Zheng, Zhiwei, et al.
Publicado: (2022)

Cost-effectiveness analysis of genotype screening and therapeutic drug monitoring in patients with inflammatory bowel disease treated with azathioprine therapy: a Chinese healthcare perspective using real-world data
por: Zeng, Dayong, et al.
Publicado: (2021)

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
por: Takumida, Hiroshi, et al.
Publicado: (2021)

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
por: Chen, Pingyu, et al.
Publicado: (2022)

Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
por: Isla, Dolores, et al.
Publicado: (2023)

The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis
por: Wu, Bin, et al.
Publicado: (2020)

A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC
por: Halmos, Balazs, et al.
Publicado: (2020)

Keynote 42: Pembrolizumab, PD-L1, and where to draw the line
por: Isaacs, James, et al.
Publicado: (2020)

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC
por: Garassino, Marina C., et al.
Publicado: (2022)

Cost-Minimization Analysis of Pembrolizumab Monotherapy Versus Nivolumab in Combination with Ipilimumab as First-Line Treatment for Metastatic PD-L1-Positive Non-small Cell Lung Cancer: A US Payer Perspective
por: Qiao, Nan, et al.
Publicado: (2021)

Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report
por: Nishii, Yoichi, et al.
Publicado: (2022)

Pembrolizumab Plus Chemotherapy in Metastatic Thymic Carcinoma: A Case Report
por: Thomas, Quentin Dominique, et al.
Publicado: (2022)

Cost-effectiveness analysis of pembrolizumab vs. chemotherapy as second-line treatment for advanced esophageal carcinoma in the United States
por: Hu, Jia, et al.
Publicado: (2022)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
por: Zeng, Xiaohui, et al.
Publicado: (2019)

First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset
por: Satouchi, Miyako, et al.
Publicado: (2020)

First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset
por: Satouchi, Miyako, et al.
Publicado: (2021)

A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland
por: Barbier, Michaela Carla, et al.
Publicado: (2021)

Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer
por: Gorshein, Elan, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status
por: Liu, Guoqiang, et al.
Publicado: (2021)

Prophylaxis for Pneumocystis carinii pneumonia in non-Hodgkin’s lymphoma undergoing R-CHOP21 in China: a meta-analysis and cost-effectiveness analysis
por: Huang, Xiaojia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sas7ulpm204fqo64agcane4367